We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tempus AI Expands Strategic Collaborations to Drive Future Growth
Read MoreHide Full Article
Key Takeaways
TEM expands collaborations to strengthen its precision medicine presence and drive future revenue growth.
TEM's expanded collaboration supports potential commercialization of Moderna and Merck's cancer therapy.
Tempus extends its Recursion data deal through 2029, securing $42M in payments and access to its RNA model.
Tempus AI (TEM - Free Report) is expanding its presence in precision medicine through collaborations, which may support future revenue growth. In line with this, Tempus entered an expanded multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy developed by Moderna and Merck and evaluated with KEYTRUDA in patients with resected stage IIB-IV melanoma and other cancers. Under the collaboration, Tempus will coordinate the collection and transfer of tumor tissue and blood samples for next-generation sequencing (NGS) and, subject to regulatory approvals, provide NGS services to support therapy design and manufacturing.
Tempus extended its data partnership with Recursion Pharmaceuticals, Inc. (RXRX - Free Report) through November 2029. As part of the extension, the companies amended the original agreement’s annual license fees, replacing discretionary payments of up to $84 million over the next two years with committed payments totaling $42 million over the next three years. Under a separate agreement, Recursion also granted Tempus a non-exclusive, worldwide license to its proprietary RNA Foundation Model, TxFM.
Tempus partnered with Angiosarcoma Awareness, Inc. to advance data-driven research into angiosarcoma, a rare and aggressive cancer. The collaboration will leverage Tempus’ analytical resources and approximately 600 de-identified patient records with paired DNA and RNA sequencing data and available clinical information to deepen understanding of the disease.
Peer Update
Doximity (DOCS - Free Report) announced an integration with Aledade, a physician-led leader in value-based care. The agreement will integrate Doximity’s HIPAA-compliant Clinical AI Suite, including its Scribe ambient notetaking tool and Ask clinical AI assistant, into Aledade Assist, an EHR overlay that provides clinical insights at the point of care.
Natera (NTRA - Free Report) entered a national partnership with Susan G. Komen, the world’s leading breast cancer organization. Together, the companies aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera will serve as the 2026 Premier National Series Sponsor of the Susan G. Komen Race for the Cure and MORE THAN PINK Walk events. Through this, Natera will help raise awareness of breast health, support patients and survivors and advance Komen’s mission to save lives.
TEM’s Stock Price Performance
In the past year, Tempus’ shares have lost 24.9% compared with the industry’s 5.7% decline.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 6.73X compared with the industry average of 4.90X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus’ loss per share estimate for 2026 has remained unchanged.
View the Zacks #1 Rank List
Image: Bigstock
Tempus AI Expands Strategic Collaborations to Drive Future Growth
Key Takeaways
Tempus AI (TEM - Free Report) is expanding its presence in precision medicine through collaborations, which may support future revenue growth. In line with this, Tempus entered an expanded multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), an individualized neoantigen therapy developed by Moderna and Merck and evaluated with KEYTRUDA in patients with resected stage IIB-IV melanoma and other cancers. Under the collaboration, Tempus will coordinate the collection and transfer of tumor tissue and blood samples for next-generation sequencing (NGS) and, subject to regulatory approvals, provide NGS services to support therapy design and manufacturing.
Tempus extended its data partnership with Recursion Pharmaceuticals, Inc. (RXRX - Free Report) through November 2029. As part of the extension, the companies amended the original agreement’s annual license fees, replacing discretionary payments of up to $84 million over the next two years with committed payments totaling $42 million over the next three years. Under a separate agreement, Recursion also granted Tempus a non-exclusive, worldwide license to its proprietary RNA Foundation Model, TxFM.
Tempus partnered with Angiosarcoma Awareness, Inc. to advance data-driven research into angiosarcoma, a rare and aggressive cancer. The collaboration will leverage Tempus’ analytical resources and approximately 600 de-identified patient records with paired DNA and RNA sequencing data and available clinical information to deepen understanding of the disease.
Peer Update
Doximity (DOCS - Free Report) announced an integration with Aledade, a physician-led leader in value-based care. The agreement will integrate Doximity’s HIPAA-compliant Clinical AI Suite, including its Scribe ambient notetaking tool and Ask clinical AI assistant, into Aledade Assist, an EHR overlay that provides clinical insights at the point of care.
Natera (NTRA - Free Report) entered a national partnership with Susan G. Komen, the world’s leading breast cancer organization. Together, the companies aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera will serve as the 2026 Premier National Series Sponsor of the Susan G. Komen Race for the Cure and MORE THAN PINK Walk events. Through this, Natera will help raise awareness of breast health, support patients and survivors and advance Komen’s mission to save lives.
TEM’s Stock Price Performance
In the past year, Tempus’ shares have lost 24.9% compared with the industry’s 5.7% decline.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 6.73X compared with the industry average of 4.90X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus’ loss per share estimate for 2026 has remained unchanged.
Image Source: Zacks Investment Research
TEM currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.